Blume-Jensen Peter
Insider CIK 1950499 · ACRV President and CEO, Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| ACRV Acrivon Therapeutics, Inc. | S Sale | 2026-08-25 | 2026-08-27 | 14,036 | $2.21 | $31.0K | 2,230,052 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | S Sale | 2026-08-25 | 2026-08-27 | 14,036 | $2.21 | $31.0K | 2,230,052 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | S Sale | 2026-08-18 | 2026-08-20 | 484 | $2.01 | $973 | 385,859 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | S Sale | 2026-08-18 | 2026-08-20 | 1,229 | $2.01 | $2.5K | 2,244,088 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | S Sale | 2026-08-18 | 2026-08-20 | 484 | $2.01 | $973 | 385,859 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | S Sale | 2026-08-18 | 2026-08-20 | 1,229 | $2.01 | $2.5K | 2,244,088 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | F Tax w/h | 2026-05-21 | 2026-05-26 | 13,729 | $1.79 | $24.6K | 2,245,317 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | A Award | 2026-05-18 | 2026-05-20 | 180,095 | — | $0 | 2,259,046 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | A Award | 2026-05-18 | 2026-05-20 | 72,706 | — | $0 | 386,343 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | F Tax w/h | 2026-05-14 | 2026-05-18 | 490 | $1.92 | $941 | 313,637 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | F Tax w/h | 2026-05-14 | 2026-05-18 | 1,253 | $1.92 | $2.4K | 2,078,951 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | A Award deriv | 2026-03-01 | 2026-03-03 | 417,210 | — | $0 | 417,210 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | A Award deriv | 2026-03-01 | 2026-03-03 | 185,495 | — | $0 | 185,495 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | F Tax w/h | 2026-02-21 | 2026-02-24 | 14,265 | $1.53 | $21.8K | 2,080,204 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | F Tax w/h | 2026-02-14 | 2026-02-18 | 1,302 | $1.63 | $2.1K | 2,094,469 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | F Tax w/h | 2026-02-14 | 2026-02-18 | 579 | $1.63 | $944 | 314,127 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | P Buy | 2026-01-14 | 2026-01-16 | 49,000 | $1.68 | $82.3K | 2,095,771 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | F Tax w/h | 2025-11-21 | 2025-11-25 | 19,904 | $2.30 | $45.8K | 2,046,771 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | F Tax w/h | 2025-11-14 | 2025-11-18 | 59,765 | $2.24 | $133.9K | 2,066,675 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | F Tax w/h | 2025-11-14 | 2025-11-18 | 490 | $2.24 | $1.1K | 314,706 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | F Tax w/h | 2025-08-21 | 2025-08-25 | 19,905 | $1.32 | $26.3K | 2,126,440 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | F Tax w/h | 2025-08-14 | 2025-08-18 | 59,766 | $1.39 | $83.1K | 2,146,345 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | F Tax w/h | 2025-08-14 | 2025-08-18 | 490 | $1.39 | $681 | 315,196 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | F Tax w/h | 2025-05-21 | 2025-05-23 | 19,904 | $1.15 | $22.9K | 2,206,111 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | F Tax w/h | 2025-05-14 | 2025-05-16 | 59,766 | $1.14 | $68.1K | 2,226,015 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | F Tax w/h | 2025-05-14 | 2025-05-16 | 491 | $1.14 | $560 | 315,686 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | A Award deriv | 2025-03-01 | 2025-03-04 | 390,390 | — | $0 | 390,390 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | A Award deriv | 2025-03-01 | 2025-03-04 | 140,540 | — | $0 | 140,540 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | F Tax w/h | 2025-02-21 | 2025-02-25 | 19,904 | $5.54 | $110.3K | 2,285,781 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | F Tax w/h | 2025-02-14 | 2025-02-19 | 579 | $5.42 | $3.1K | 316,177 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | F Tax w/h | 2025-02-14 | 2025-02-19 | 37,152 | $5.42 | $201.4K | 2,305,685 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | F Tax w/h | 2024-11-21 | 2024-11-25 | 19,910 | $6.44 | $128.2K | 2,342,837 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | F Tax w/h | 2024-11-14 | 2024-11-18 | 490 | $7.92 | $3.9K | 316,756 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | F Tax w/h | 2024-11-14 | 2024-11-18 | 59,766 | $7.92 | $473.3K | 2,362,747 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | F Tax w/h | 2024-08-21 | 2024-08-23 | 79,616 | $9.19 | $731.7K | 2,422,513 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | F Tax w/h | 2024-08-14 | 2024-08-16 | 59,765 | $7.02 | $419.6K | 2,502,129 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | F Tax w/h | 2024-05-14 | 2024-05-16 | 54,918 | $8.36 | $459.1K | 2,561,894 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | A Award deriv | 2024-03-01 | 2024-11-27 | 90,090 | — | $0 | 90,090 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | A Award deriv | 2024-03-01 | 2024-11-27 | 225,226 | — | $0 | 225,226 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | F Tax w/h | 2024-02-14 | 2024-02-16 | 41,861 | $3.40 | $142.3K | 2,616,812 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | F Tax w/h | 2023-11-14 | 2023-11-16 | 239,023 | $5.08 | $1.21M | 2,658,673 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | A Award | 2023-08-21 | 2023-08-23 | 493,994 | — | $0 | 2,897,696 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | M Exercise deriv | 2023-05-31 | 2023-06-01 | 33,605 | — | $0 | 90,855 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | M Exercise | 2023-05-31 | 2023-06-01 | 33,605 | $3.88 | $130.4K | 2,403,702 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | A Award deriv | 2022-11-14 | 2022-11-16 | 80,120 | — | $0 | 80,120 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | A Award deriv | 2022-11-14 | 2022-11-16 | 180,269 | — | $0 | 180,269 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | A Award | 2022-11-14 | 2022-11-16 | 60,090 | — | $0 | 2,370,097 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | A Award | 2022-11-14 | 2022-11-16 | 26,707 | — | $0 | 320,705 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | A Award | 2022-11-14 | 2022-11-16 | 934,731 | — | $0 | 1,806,588 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | A Award | 2022-11-14 | 2022-11-16 | 503,419 | — | $0 | 2,310,007 | SEC↗ |